Trending Now
LFJ Conversation

An LFJ Conversation with Steve Nober, Founder/CEO of Consumer Attorney Marketing Group

By John Freund |

An LFJ Conversation with Steve Nober, Founder/CEO of Consumer Attorney Marketing Group

Steve Nober, the founder and CEO of Consumer Attorney Marketing Group (CAMG), has been a significant force and innovator in the legal marketing industry for over 15 years. Often hailed as the Mass Tort Whisperer℠, Nober earned his reputation through over a decade of spearheading successful mass tort campaigns and fostering close relationships with top handling firms, showcasing unparalleled expertise in the mass tort arena. He is a sought-after speaker, presenting at over 40 conferences annually, across the United States and globally, covering a range of topics, including best marketing practices, ethics in advertising, and litigation funding. Under Nober’s leadership, CAMG has grown into the largest fully integrated legal marketing agency in the United States, steadfastly committed to its core values of ethics first, transparency, innovation, and efficiency. With a remarkable career spanning over 30 years, Steve Nober has demonstrated executive leadership and innovation in marketing, media management, and digital and computer technologies. His experience includes managing mergers and acquisitions, corporate turnarounds, and startups. In the advertising sector, his specialties include direct response marketing, digital and offline advertising, and lead generation strategies, as well as media buying and analysis, particularly focused on the legal sector. Below is our LFJ Conversation with Steve Nober: CAMG breaks down mass tort claims into early, mid and late stage. These are segmented by expected time to settlement, with early being 30-48 months, mid being 18-30 months, and late being 6-18 months.  How does the value-add of CAMG change as cases make their way from early to mid to late stage?   The value CAMG brings to each stage is a bit different and I will explain. The first value proposition CAMG bring to clients for early-stage cases is similar to the answer to your question 3 below in regards the modeling, leveraging historical data, targeting and projecting what the origination costs will look like is key to being ready to jump into a new and early tort. Also, understanding criteria that leadership handling law firms would like to see used to qualify an injured victim is critical to have knowledge before starting.  Also, in this early stage knowing who the key handling law firms that are going to make a move to be in leadership for the various torts is a key decision that needs to be made as all things are set up to begin.   These are all part of the CAMG process to help our clients begin deploying capital into the early stage torts.
I am often referred to as “The Mass Tort Whisperer®” which really means we are usually very early in hearing about early new torts, late-stage torts that may be settling soon, etc.
This information can be traded on so it’s quite valuable as we can help our clients use much of this information to make capital deployment decisions. The value for mid stage is a combination of value we bring for early and some of the value propositions mentioned in late stage. Knowing the handling firms that have been really serious about the tort and in leadership is key.  The modeling financials can get more detailed with projections and less guessing since the tort will have moved from early to mid-stage.  Following the tort activity in the litigation is key to understanding the direction that leadership sees for each tort and how bullish they are is key to an investor deciding to deploy capital for the tort.    Our value for the mid stage is key being the tort is mid-way thru the life cycle and so many variables need to be considered prior to investing. The value of late stage is knowing which law firms would be considered the best handling firm to work with that can maximize settlement values or which firms are in settlement negotiations and can still take more cases would be two good examples. Also, having the data to model out what fallout/attrition looks like with late-stage cases is key since it may be higher than the earlier stages.   The late-stage torts are a great opportunity but financial modeling and picking the right partners are key.  Also, the marketing/origination of cases needs to be handled very precise and almost scientific like to make sure cases can still be acquired at costs that make sense taking the criteria in mind of the possible handling firms.  There’s quite a bit of value we bring to these late-stage campaigns for our clients. At which stage of the case life are you currently finding the most attention from litigation funders?  Where is there the most room for growth?  The most attention goes to late-stage torts due to the projected shorter time to settlement vs. the early and mid-stage torts.  If there’s more capital to spend annually, we see more diversification with the heavy weight still on late stage and smaller percentages of total capital going to the mid and early stages. We educate our clients on costs and risk for each stage tort.  The late stage is typically higher, but risk of a settlement is much lower since it’s a mature tort, there’s more history and analysis that can be done on how the tort has progressed.   The early torts are just emerging or will have recently passed Daubert so being early the costs are much lower and risk a bit higher since the litigation will be early in starting.  Mid stage gives you a bit of all with costs not as high as late stage and risks a bit lower than the torts just starting out.
There are a limited number of injured victims in each tort, and we always need to be careful not to put more capital than we project we can spend, or costs of a case will drive higher pretty fast.
With larger capital clients we are moving into other torts whether late stage as well or mid and early stages to help diversify. One interesting note as we diversify clients is deploying capital into some torts that are closer to personal injury cases vs. traditional mass torts like Asbestos and Sex Abuse as two examples.  The time to settlement in these are closer to what we see in auto accidents being around 18 months, these are interesting torts to diversity capital and see shorter settlement times that some of the longer mass torts. The answer to the question about where room for growth is would be from the early-stage torts in being that there typically has not been a large amount of marketing yet to acquire cases so the possible total cases available would be quite high and with costs being fairly low.   This is usually where we can deploy the most capital vs. the other stages. When it comes to modeling out the expected costs, timeline and return, you look at a variety of factors here.  Can you explain what those factors are, and how do you weight each of those from case to case (is there a standard algorithm, or is the weighting bespoke to each case?)  When modeling out the expected costs, timeline, attrition and projected return, we consider a variety of factors to ensure a comprehensive analysis. These factors can include:
  1. Historical Data: Past performance and outcomes of similar cases provide a baseline for expectations.
  2. Targeting Data: We subscribe to very sophisticated targeting and demographic syndicated services such as Kantar and Neilson.  Once we have targeting details on who the injured victims are, these targeting services help is see which advertising mediums and channels index the highest to reach them.
  3. Active Campaigns: We are typically running active campaigns for most of the more popular mass torts so building up recent cost details is something we are looking at every day to optimize the performance response data which keeps costs of origination lower by being very quick to move capital where response and quality of cases are best and stop the capital spend in areas that are not showing a response that makes sense to continue.  This is Moneyball for Marketing, and I speak about this often at conferences.
  4. Market Conditions: Current trends in the legal market and any external factors that might affect the case.
  5. Attrition or Fallout: This is key with modeling out costs of originating a real quality case.  We watch very close as the tort matures from early to mid to late stage how the fallout or attrition of the new signed case is trending.  Once a claimant is signed with a law firm, some of these will not turn into a case as all of things are verified.  Medical records for example will always have a percentage of cases where there are no medical records or the records show a different injury, etc.  These need to be projected into the modeling at the very beginning and they vary from tort to tort.
  6. Intel from Leadership Firms: Our relationship with firms in leadership allow us to receive regular updates on the estimated timeline and estimated settlement values.
As for the weighting of these factors, it tends to be bespoke rather than algorithmic. Each case is unique, and while we do use historical data and standard metrics as a starting point, the specific circumstances of each case require a tailored approach.  The key metrics are seeing where the full costs are to originate compensable case and what the projected settlement range looks like so the various torts can be compared from an ROI analysis. You provide a wealth of intelligence through your Legal Marketing Index.  What can law firms and litigation funders expect to find there, and how is this intelligence useful?  We publish what we call the Legal Marketing Index or LMI for short and this is what we use to provide some of the data we collect that we share with the industry.  This data is broken down by each mass tort and includes extensive details that we have aggregated from large case volume so the data tends to be spot on as a baseline on what we see and can be expected if a law firm or fund wants to move to be active in a particular tort.  We are publishing date on topics such as injury details, demographics, geographics, case concentration in cities around the country, media details, call details, etc. Some of the intelligence is useful and some just interesting to review.  An example of how the data is critical to know before moving into acquiring cases for a tort would be the following:  If you wanted to acquire hernia mesh cases but knew that only a few manufactures are defendants and the rest of the hernia mesh devices do not make sense hold onto as a case, knowing what percentage of cases of every 1,000 are which manufacturer’s would be key to calculating the real costs of finding the right hernia mesh cases with the right manuf. Product vs. all others not making sense to keep.    People who have had hernia mesh surgeries usually have no idea which manufacture mesh device was used so when signing these cases there is no way to know how many are actually going to be what you were looking for until medical records are pulled which can me many months down the line.  So, being able to predict before starting what those percentages will be is critical to calculating costs on cases and to see if the ROI is enough to move ahead or not. One more example would be Talc cases which cause ovarian cancer and defendant is Johnson & Johnson.  This litigation has gone on for quite a while so now many of the cases signed end up not being a good case to keep so there’s fallout or what we call attrition after medical records are pulled.  Having this recent fallout data from the medical records with a sampling of a large pool of records is key to the modeling ahead of time and again, to see if ROI makes sense to move ahead given the fallout may be quite high. A third example would be for the litigation PFAS and the leadership handling firms have set a fixed criteria on which cancers they would accept and sign a claimant vs. others they would not sign.  We collect the data on “type of cancer” for thousands of calls and have published the breakdown of each cancer callers have in descending order.  A review of this data would help see for every 10 or 100 calls from victims who may qualify, how many from the total would have a qualifying cancer.  Again, this helps project out costs of a case to sign using the data to help model correctly. These are just a few quick examples of how some of the data we publish is quite valuable to firms looking to move into the various mass torts. What are some of the main questions / concerns you receive from litigation funders, and how do you address these?  Here are a few of the more common questions we get from litigation funders: What are your investment minimums? While we have no minimums, we don’t think the funding program makes sense for less than $2m-$3M as a minimum if that helps the fund with getting started.  Averages tend to be more like $5m-$10M as first run and many come to us with $20M+ as first year to start.   How long does it take for you to deploy capital? That depends on market conditions and performance of each tort but typically we are starting and originating cases within a week of receiving capital so it’s usually quite fast to start.   We have weekly meetings with our clients to discuss the most intelligent deployment strategy taking all things into consideration at that time. We are always sensitive to scaling while keeping acquisition costs within the forecasted range What is your primary role? The primary role is to manage the curated program which includes many pieces.  I would say the actual origination of cases which includes the marketing, call center screening & case signing is primary.   Not to take away from how critical the financial modeling, handling firm choices and leveraging our relationships with these handling firms is key.  There are many key value pieces we bring to a client of ours so tough to answer since we think all are so important. Does a funder client of CAMG have to use a handling law firm CAMG introduces or can we they use their own existing relationships?
We are happy to collaborate with your existing law firm relationships, but we really try to stick to the requirements we think make for a great handling firm and we would want to see if the law firm you may want to use meets the standard.
The key things we look for are the following:
  • Are they in leadership in the MDL for the tort being discussed.
  • Are they a real trial firm with a rich history of litigating cases and a threat to the defendants?
  • Do they have the infrastructure to take on more cases from this program
  • Will they agree to an equity split on the partnership that we think makes sense
  • Are they good people to work with in general
Choosing the right handling firm has never been more important considering how many of the settlements have been structured the last few years.

About the author

John Freund

John Freund

More LFJ Conversations

View All
LFJ Conversation

An LFJ Conversation with Logan Alters, Co-Founder & Head of Growth at ClaimAngel

By John Freund |

Logan Alters is the Co-Founder and Head of Growth at ClaimAngel, the nation's first transparent legal-funding marketplace. He built the company from a concept into a nationwide platform trusted by 500+ law firms, 25+ funders, and 20,000+ fundings at $100M+ in volume, all at one standardized rate. Before ClaimAngel, Logan worked across MedTech, consumer products, and venture capital. He earned his degree from UC Berkeley Haas School of Business in three years while competing as a Division I point guard.

Below is our LFJ Conversation with Logan Alters:

ClaimAngel positions itself as a transparency-first platform at a time when plaintiff funding is facing heightened scrutiny from regulators and bar associations. How do you see ethics, disclosure, and alignment with ABA and state rules reshaping the future of the industry, and what specific standards is ClaimAngel trying to institutionalize?

We started ClaimAngel because we saw a gap that nobody was closing. Plaintiffs have access to a new asset, their case, but the industry built to serve them wasn't working. There are more than a thousand funding companies in the U.S., each setting its own rates, contracts, and processes. That fragmentation created an environment where anything goes. Rates compounded in ways clients couldn't understand until settlement. Fees got buried in contracts. Law firms experienced the frustration firsthand or heard the stories and decided not to recommend funding at all. The whole system defaulted to relationships over results: who you knew mattered more than what you offered. Funders competed for access instead of competing on terms. That model doesn't scale, and it doesn't serve plaintiffs.

That's the problem we set out to solve. Not by becoming funder #1,001, but by building marketplace infrastructure. In 2023, we pitched Morgan & Morgan's executives on a different future. A marketplace, not a funding company. One rate, one process, one outcome for every client. They didn't think it could be done, but they believed in the mission. John Morgan recently called ClaimAngel the Charles Schwab of client funding. The comparison resonated with us because it captures exactly what we're building. Schwab didn't invent investing. He standardized it. He made access equal and fees transparent. Before Schwab, Wall Street rewarded insiders. After Schwab, everyone got the same deal. Plaintiff funding is at that same inflection point.

We've now processed more than $100 million in volume across more than 20,000 fundings. Every contract includes plain-English rate disclosures. Every case shows plaintiffs what they'll owe at settlement before they sign and at any time in their portal. That's the standard: no surprises, no fine print. That's not a pilot. That's proof the model works.

We're not a funder. We're the infrastructure that makes funding predictable, transparent, and aligned with what plaintiffs and law firms actually need. When every client gets the same terms, and every contract looks the same, there's nothing to hide from regulators or bar associations. Standardization is the compliance solution.

The industry has operated like the wild west for too long. Regulators are stepping in. Bar associations are paying attention. Law firms are already choosing partners based on compliance and transparency, not relationships. That's the shift. More than 500 firms have at least one client funded through ClaimAngel. The next chapter will be defined by who builds the standard, not who has the best relationships. That's what we're here to do.

You describe plaintiff funding as being at a pivotal moment where opaque, high-rate transactions are giving way to marketplace models. What pressures or structural changes are driving that shift, and why is standardization becoming a competitive advantage?

The old model is breaking down. Not because anyone decided it should, because the market moved.

Law firms are shifting their focus toward efficiency and growth, minimizing anything that creates friction. They want funding that helps them maximize case value, not funding that eats into their fees at settlement. A firm managing thousands of cases can't afford the chaos of tracking liens with unpredictable compounding rates that make settlements harder to close. They want one process that works every time.

This is especially true for smaller firms. A solo practitioner or ten-person shop just wants to practice law. They don't want funding to become another thing they have to manage. Standardization means funding works as a tool in the background, not an encroachment on how they run their practice.

People are more financially aware than they were ten years ago. They understand interest. They ask about caps. They compare terms. The days of burying fees in contracts and hoping no one notices are over. When clients ask questions, firms need answers they can stand behind.

On the other side of the table, insurance carriers are already ahead. They use data to model case values, they identify plaintiffs under financial pressure, and they extend timelines knowing desperate clients will settle for less. Their algorithms win. When a plaintiff can't afford to wait, the carrier knows it, and the offer reflects that weakness. As funding becomes more widespread and predictable, carriers will have to adjust. Plaintiffs who can afford to be patient change the calculus entirely. That's the power of standardized funding.

Capital markets are moving too. Litigation finance is maturing into a real asset class, and institutional money is looking for places to deploy. But capital doesn't flow into fragmentation. A thousand funders with a thousand different rate structures and contract terms isn't investable infrastructure. Standardization is what unlocks scale. It's what allows the industry to grow from a few billion dollars to tens of billions deployed annually.

These forces aren't pushing toward a slightly better version of the old model. They're pushing toward new infrastructure. The companies that figure this out early will define the next era of plaintiff funding.

Your Rule of One framework aims for one rate, one process, one outcome. Why pursue a true standard instead of a traditional pricing strategy, and how do you respond to funders who argue flexibility is necessary for risk management?

One rate. One process. One outcome. That's not a tagline. It's the entire model.

A client knows exactly what they will owe. A law firm knows what a lien looks like at any point. No surprises. No shifting rates. No complicated projections. Simplicity isn't a marketing angle. It's a consumer protection tool and an operational stability tool for firms of any size.

The old model worked differently. Every funder created its own rate structure, contract terms, and interpretation of risk. Most clients don't understand why a four percent monthly compounding rate leads to a 6x repayment in 24 months. That complexity benefits only the insiders who understand it.

Bob Simon at Simon Law Group put it simply: lawyers have an ethical duty to do what's best for their clients. If a client needs access to capital to care for themselves or loved ones, you should help them find the lowest interest rate. That's not optional. It's the job.

The consequences of getting it wrong are real. Firms inherit cases all the time where the previous attorney used funding with poor terms, and by the time the case settles, the client's net is so low the case can't even settle. It leads to law firm fee reductions or the client drops the firm or it goes to trial. That's not what plaintiff funding is supposed to do.

Funders often defend rate flexibility as risk management. But pricing in plaintiff funding didn't evolve from risk. It evolved from fragmentation. With no shared standard, companies layered compounding, step-ups, duration triggers, underwriting fees, broker fees that can reach twenty percent, and buyout fees. None of this reflects actual case risk. It reflects legacy complexity built in isolation.

That complexity helped keep plaintiff funding adoption stuck at four to six percent of the total potential market. Rates rose so high that funding became a last resort. Yet more than ninety-seven percent of personal injury cases settle or win. When an asset class has a loss profile comparable to credit card defaults, extreme pricing is hard to defend. Real risk management comes from disciplined underwriting, transparency, and fair pricing, not stacking fees to justify high rates.

Standardization isn't a constraint. It's the path to mass adoption. The Rule of One isn't a theory. It's 20,000+ fundings across 500+ firms. That's proof at scale.

You’ve set a standardized rate of 27.8 percent simple annually with a 2x cap. What was the economic thinking behind those parameters, and how does this model align incentives across plaintiffs, law firms, and funders?

We didn't start by asking what rate we could charge. We started by asking who we're actually competing with.

Ninety-five percent of plaintiffs don't use plaintiff funding. When someone is injured, out of work, and waiting on a claim, they reach for credit cards and personal loans. That's the market we're converting.

The problem is that consumer credit wasn't built for a plaintiff's reality. It prices the borrower, not the case. It assumes steady income and monthly payments. A plaintiff has access to a new asset, their case, but a credit card can't tap into that. The pressure spills onto law firms and ultimately the settlement.

So we worked backward from that reality. If we want to convert plaintiffs away from credit cards, we need to beat credit card economics for someone who can't work, can't make monthly payments, and doesn't know when their case will settle. That's how we arrived at 27.8 percent simple rate with a 2x cap.

Here's what that looks like in practice. A plaintiff who takes $5,000 and settles in 18 months owes around $7,400 with all fees. With a typical compounding product with a slew of origination and servicing fees, that same funding could easily exceed $15,000. That difference is the gap between a client who walks away whole and a client who resents their attorney.

For funders, the math works if they're willing to evolve. The old model delivered returns that would make a hedge fund blush, but in just a small percentage of cases. Our model delivers lower per-case returns but at scale, with fast capital deployment, consistent servicing, and a loss rate in the single digits, comparable to credit card defaults. The key is predictability. Our 27.8% annual rate (no compounding ever) works out to 6.95% every three months until settlement or the 2x cap. The 2x cap means a plaintiff who takes $5,000 will never owe more than $10,000, and that cap doesn't hit until 46 months. Most "2x caps" in the industry hit at one, two, or three years. Ours gives plaintiffs nearly four years.

That rate is only sustainable because our marketplace collapsed the cost structure. Traditional models relied on sales teams, manual deployment, and relationship-driven acquisition. That overhead required high rates. Our marketplace removes most of that friction. No sales cycle, no manual underwriting queues, standardized processes across every case. Efficiency and market competition make a lower rate viable. Insurance carriers already use data to identify weak and desperate plaintiffs. Our marketplace gives funders the same advantage. We standardized underwriting with quality case data (injury details, liability, policy limits, case docs, and more), so funders make calculated decisions in minutes instead of reputation-based approvals. Lower costs and disciplined underwriting mean we can sustain 27.8% at scale. It's a different business. It requires funders who see where the industry is going and law firms that recognize their clients deserve better. We've built the infrastructure to make that easy.

The legacy model asked: how much can we charge? We asked: how do we convert the ninety-five percent? One question builds an industry. The other protects a margin.

You’ve argued that plaintiff funding is best understood as a tool that converts time into negotiating power. How does ClaimAngel’s marketplace help plaintiffs stay in the fight longer and capture more of their claim’s true value?

How many situations in life can you actually buy time? That's what plaintiff funding is. Not debt. Not a loan. Time. And when you have a legal case, time is power.

When someone is injured and out of work, time is the one thing they don't have. Bills pile up. Pressure builds. Insurance carriers know this and wait. The longer a plaintiff can't afford to hold out, the lower the offer. That's not negotiation. That's leverage working against the people who need it most.

Funding flips that dynamic. A plaintiff who can pay rent and cover medical bills while their case develops is a plaintiff who can wait for the right offer. That's why they hired their attorney in the first place: to fight for the true value of their claim, not to take the first check that shows up.

When plaintiffs have time, law firms can do the work they were hired to do. Gather full medicals. Wait for maximum recovery. Push back on lowball offers. The cases that settle for $40,000 under pressure become six-figure results when the client isn't calling every day saying they need the money now. One client told us she was three days from losing her apartment when she got funded. Eighteen months later, her case settled for six figures. That's what time buys. Firms get more revenue with less pressure to settle early. Clients walk away with what they deserve from the start.

But here's the problem with traditional funding: time is power until settlement day, when it turns into kryptonite. A plaintiff who borrowed $5,000 at compounding rates suddenly owes $15,000+. The attorney's fee gets reduced. The client's net recovery shrinks. Everyone fought for two years to maximize the settlement, and the funding lien swallows the value. That's not time as power. That's time as extraction. Our model solves this. At 27.8% simple with a 2x cap, that same $5,000 costs $7,400, not $15,000. The client and attorney walk away with what they earned. Time stays power, even at settlement.

That's what ClaimAngel's marketplace delivers. In traditional funding, a plaintiff applies to one funder, waits for approval, and might get rejected. Then they start over. Our marketplace removes that friction. Multiple funders see the case simultaneously. Standardized terms mean no negotiation. A plaintiff who applies Monday can have funding by Wednesday. When you're three days from losing your apartment, that speed is the difference between staying in the fight and taking whatever offer is on the table.

The industry maximized what plaintiffs owe. We maximize what plaintiffs keep.

LFJ Conversation

An LFJ Conversation with Ian Garrard, Managing Director of Innsworth Advisors

By John Freund |

Ian Garrard is the managing director of Innsworth Advisors Limited, the advisor and manager to the funds that provide third party litigation funding for high value claims in the UK, EU and US.

Claims under management include high profile and groundbreaking claims in the UK’s Competition Appeal Tribunal against Meta and Amazon, claims in the Netherlands against Oracle and Salesforce, as well as claims against VW in Germany and Apple in the US.  Before moving into litigation funding, Ian was a lawyer in private practice (on financing, restructuring and litigation matters) as well as a founder of specialist law firms and an advisor to major oil & gas interests on exploration and production assets.

Below is our LFJ Conversation with Ian Garrard:

The claim against Rightmove alleges that the portal charged estate-agents “excessive and unfair” listing fees, and that the action will proceed on an opt-out basis for thousands of agencies. What specifically attracted Innsworth to fund this case, and how does it fit with your overall litigation-funding strategy? 

Your readers will appreciate that we can’t say too much at this early stage, but on our evaluation it is a strong case on its merits, with a considerable amount of harm caused to the proposed class of businesses. Jeremy Newman, the proposed class representative and a former CMA panel member has an excellent team supporting him, led by lawyers from Scott+Scott UK LLP. Innsworth is a committed funder of opt out collective actions in the Competition Appeal Tribunal and this case fits squarely within our focus. More information on the claim is available at rightmovefeesclaim.com.

More generally, this is an exciting time for us. We are funding three other opt out claims in the CAT and we have just announced a claim on behalf of Uber drivers in the UK and Europe, which alleges that Uber has unlawfully used automated decision-making, including profiling, in its pricing systems to dynamically set driver pay by algorithm and reduce their take-home pay. If the claim doesn’t settle in the pre-action phase then the intention is to issue collective proceedings before the Amsterdam District Court in the Netherlands. We also have lots of promising cases in our pipeline at the moment, working in collaboration with a range of London and EU based law firms.

Opt-out class actions in the UK’s competition-law space have historically faced procedural and payout-challenges. How is the funding arrangement structured in this Rightmove claim to align incentives across Innsworth, the claimants, and their legal counsel? 

There has been much said and written about the challenges the UK’s opt out regime is working through - including the need to balance reasonable certainty as to the level of returns a funder will derive and the desire to ensure that the regime delivers for the benefit of the class. The benefit of any recovery by the class comes at a cost - as in any commercial context – and the CAT to its credit recognises the importance of third party funding to the functioning of the opt-out regime. Recognising this and the interests of the class, the funding is structured in a way that seeks to align those interests.

From a business model perspective, Rightmove commands a dominant share of UK property-portal traffic and listings (reportedly over 80%). How do you assess the strength of the antitrust and competition arguments in the claim, and how does Innsworth evaluate the potential for a precedent-setting outcome if the tribunal rules favourably? 

The Rightmove fees claim announcement follows a series of English unfair pricing judgments which have gone a long way to clarify how an English court or tribunal will approach these kinds of cases. Rightmove uses its high market share as a marketing tool and has achieved sky-high margins over many years, achieved through regularly increasing its prices.  Many agents feel they have no choice but to be on Rightmove and Rightmove knows that. Commentary from industry figures following the announcement of the claim has highlighted how strongly many class members feel about Rightmove’s pricing.

Litigation funding in large scale opt-out claims is increasingly visible to institutional investors. How does Innsworth view its role as a funder in terms of transparency, reputation-risk management, and alignment with claimant-interests?   

We take our role as a stakeholder in the UK (and global) litigation funding community very seriously and we are confident in the value that our funding provides. The service we provide, of non-recourse funding, protects claimants against the costs of litigation.

If our funding unlocks redress for a class, that is a recovery for those harmed that would not otherwise have been achieved, so there is therefore a synergy between the interests of a funder and a class harmed by breach of competition law.  Innsworth is transparent about its funding and terms of funding in the Competition Appeal Tribunal.

We do think there is a debate to be had about whether defendants should have access to financial information on e.g. a claim budget and funder commission. We think it’s fair that a defendant should be satisfied that a litigation funder can meet any adverse costs order made against it in an opt out claim (as England and Wales is a ‘loser pays’ jurisdiction). But currently defendants to these claims will scrutinise claim budgets and funding agreements in detail and use this to make opportunistic arguments, while claimants typically have no visibility on defendant budgets and funding. It’s an example of the information asymmetries which exist when seeking to hold dominant companies to account.

What is your take on the litigation funding market for opt out claims in England and Wales at the moment? 

We’ve seen a real slowdown in the number of claims being filed in the last year or so. A lot of this is due to uncertainty as to the level of return that the Competition Appeal Tribunal will permit a funder to receive, even if this has been freely agreed between a class representative and funder. Of course, the effect of PACCAR has made funding more challenging in England and Wales generally.

That said, Dr Kent’s recent success in her claim against Apple highlights the potential of the regime to hold dominant companies to account and to deliver meaningful redress to class members. The judgment is timely as the UK government is currently considering making reforms to the opt out regime in the face of a concerted lobbying effort from big business groups. We think the opt out regime is starting to deliver on its objective of improving competitiveness in the UK economy, so making any wholesale changes now would be counterproductive, but the prospect of reforms is adding to the uncertainty facing the regime.

LFJ Conversation

How Nera Capital Reached $150M in Investor Returns

By John Freund |
Aisling Byrne is a Director at Nera Capital, a leading litigation funder with a global footprint, where she plays a central role in driving the firm’s growth and strategic initiatives. With extensive experience in litigation funding and investor relations, Aisling focuses on building strong partnerships with law firms, funders, and stakeholders while overseeing the operational efficiency of the firm. Her leadership combines a pragmatic, solutions-driven approach with a deep understanding of both consumer and commercial claims.
Below is our LFJ Conversation with Aisling Byrne:
Nera recently passed $100 million in investor repayments, citing a “data-driven approach to case selection and risk management” as a key factor. What specific data-centric approaches have contributed the most impact?
At Nera, we see data not as a supporting tool but as the backbone of our decision-making. Our proprietary models assess thousands of variables across historical case outcomes, jurisdictional nuances, law firm performance metrics, and even the efficiency of courts. By feeding this data into predictive analytics, we can more accurately model recovery timelines and probabilities. What’s been most impactful is combining quantitative scoring with qualitative oversight—data helps us remove emotional bias, while our team of experienced professionals ensures the analysis is grounded in real-world legal and enforcement dynamics. That dual approach has allowed us to deliver consistent investor repayments while scaling responsibly.
Nera has now reached $150m in investor returns.

You secured a £20 million funding line from Fintex Capital, bolstering Nera’s ability to support consumer claims and expand funding sources. How do such funding lines influence your ability to take on riskier or less predictable claims, including those where pre-judgment attachment might play a role in enforcement?
Regardless of how many new funding lines we secure, it doesn’t mean our approach changes. In the consumer division, our strategy of supporting proven, legal precedent set claim types and claim selection criteria remains exactly the same—and that high bar has been fundamental to our success and our ability to deliver substantial repayments to investors. The additional capital simply allows us to scale what we already do well, without diluting our standards.
For investors with a different criteria, the commercial division may be better suited. Those cases can sometimes have less predictable timelines, but also offer higher potential returns. In this way, we can align capital sources and timelines with the most appropriate claim types, ensuring consistency in performance while broadening the opportunities we can pursue.

Many financialized legal claims carry the potential for post-judgment or post-award interest and/or enforcement costs. Could you speak to how Nera evaluates the enforceability of judgments, including the likelihood of successful asset attachments (domestic or abroad), in structuring returns for investors?
Enforceability is as important as the merits of the case itself. A favourable judgment is meaningless without a realistic pathway to recovery. At Nera, we always seek to avoid claims where enforceability is in doubt. Before committing, we carry out a comprehensive enforceability assessment, which includes mapping the defendant’s asset profile, reviewing local enforcement regimes, and stress-testing recovery prospects. This rigorous upfront analysis is a cornerstone of our underwriting approach, and in our 15 years of business, we have not experienced enforcement issues—a strong validation of the discipline and prudence built into our process.

Given that litigation finance is often argued to be an “uncorrelated asset class,” how does Nera balance its portfolio of consumer mass claims, commercial disputes, and potential cross-border enforcement matters to provide both stability and high upside for investors?
Diversification is central to our portfolio construction. Consumer claims tend to generate steady, repeatable outcomes that provide stability and heavy settlement cash flows. Commercial disputes, on the other hand, carry larger ticket sizes and higher upside, but sometimes involve greater complexity and longer timelines.
When it comes to cross-border enforcement matters, we take a very cautious stance. We look to avoid supporting claims where enforceability could present difficulties and always conduct an upfront enforcement assessment. By working with leading lawyers and advisers in each jurisdiction, we ensure risks are fully evaluated and mitigated before committing capital.
Because these different claim types are not only uncorrelated with traditional markets but also with one another—thanks to variations in claim structure, jurisdiction, and duration—we can actively balance short-term liquidity against long-term growth. This layered approach allows us to deliver both stability and meaningful upside, while staying true to the uncorrelated nature of litigation finance.
 

As Nera has expanded into the Netherlands and joined the European Litigation Funders Association (ELFA), what regulatory, ethical, or procedural hurdles have you confronted? How do these shape your funding models?
Europe presents both opportunities and challenges. In the Netherlands, collective redress mechanisms are still evolving, and with that comes heightened regulatory and judicial scrutiny. By joining ELFA, we’ve committed to the highest standards of transparency, governance, and ethical practice, which we see not as a constraint but as a competitive advantage.
One hurdle has been adapting our funding structures to meet jurisdiction-specific requirements, such as disclosure obligations and court oversight of funder involvement. These challenges have made us more deliberate in how we design our funding contracts and financial models, ensuring they are robust, compliant, and aligned with the long-term sustainability of the sector. Ultimately, we welcome this direction—it elevates the industry and builds trust with investors, law firms, and claimants alike.